Drugs / C19-IG20%
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04847141 | Apr → Nov 2021 | COVID-19 | Grifols Therapeutics LLC | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C19-IG20% | “administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of...” PMID 36936402 ↗ Mar 2023 |
| Modality | Protein / enzyme biologic | “Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content.” PMID 36936402 ↗ Mar 2023 |
| Route | Subcutaneous | “Participants will receive 1 gram (g) of C19-IG 20% subcutaneous (SC) infusion containing one syringe of 5 milliliters (mL) C19-IG 20% plus one syringe of 5 mL sterile 0.9%...” NCT04847141 ↗ |